Martina Molsbergen, Vice President, Business Development and Johan Kers, PhD, Vice President, Research.
| VANCOUVER, Wash., April 5, 2019 /PRNewswire/ -- Absci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced the unveiling of their 12-week cell line optimization workflow and the addition of two executive team members: Martina Molsbergen, Vice President, Business Development and Johan Kers, PhD, Vice President, Research. Martina Molsbergen, AbSci’s new Vice President of Business Development, brings more than 25 years of licensing and senior management leadership experience to the AbSci organization. She has helped to build and successfully commercialize many leading- and cutting-edge technology platforms serving in a variety of companies and executive positions including Selexis, Sorrento, Crucell, BioWa, and Patheon. Over her career, Ms. Molsbergen has completed more than 400 deals and created over $4 Billion in deal value for various companies. Johan Kers, PhD, who joined AbSci in 2018 as Director of Molecular Sciences, has been promoted to Vice President of Research. Dr. Kers is an accomplished microbiologist with expertise in synthetic biology and bioinformatics. He brings more than 13 years of leadership experience to the company with extensive experience leading teams that have developed microbial systems for the production of protein therapeutics and small molecules. Prior to AbSci, Dr. Kers held leadership positions at Joyn Bio, Ginkgo Bioworks, and Intrexon. “We have seen incredible demand for AbSci’s SoluPro platform, especially from partners with innovative and complex antibody and protein scaffolds – such as Fc-fusions, T-cell engagers, Fabs – that commonly used cell lines, including Chinese hamster ovary (CHO) platforms, cannot effectively produce. Dr. Kers and the scientific team at AbSci have developed a proprietary high-throughput optimization assay system and workflow to rapidly tailors SoluPro™ for any given molecule. This “first-of-its-kind” optimization assay system and workflow enables rapid optimization of protein titer, function, quality, and downstream processability, resulting in high-quality product and multi-gram per liter fermentation titers in 12 weeks. This fills a critical need for our partners who are trying to get their molecules into the clinic as early as possible,” said AbSci’s CEO, Sean McClain. AbSci’s breakthrough cell line optimization workflow will be the topic of Dr. Kers talk at the upcoming PEGS Summit in Boston on April 10th. For more details on the talk please visit PEGSUMMIT.com or contact kkrieger@abscibio.com About AbSci AbSci is a global leader in biomanufacturing technologies. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides to the most novel classes of biotherapeutics, at high-titers and high-quality. AbSci’s unique approach increases discovery throughput, accelerates development, reduces manufacturing costs, and increase plant capacity for the biopharmaceutical industry. For more information, please visit www.absci.com.
SOURCE AbSci |
View original content:
